This is Psychedellux, the week’s recap of psychedelic stock news. 

COMPASS Pathways plc (Nasdaq: CMPS) said it has been granted two new patents. These patents cover oral formulations of COMPASS’s synthetic psilocybin in the treatment of major depressive disorder (MDD), which includes treatment-resistant depression (TRD).

Psychedelics-inspired biotech and life sciences company Mydecine Innovations Group, a company, is now listed on the NEO Exchange, following a voluntary delisting from the Canadian Securities Exchange. Mydecine is now trading on NEO under the symbol NEO:MYCO.

MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ) announced that effective as of Friday March 19th, 2021, it has been added to the FTSE Global Micro-Cap Index (which represents $1.3 trillion in global market cap) and the FTSE Total-Cap index (which represents $54.7 trillion in global market cap).

20/20 Global, Inc. dba Mycotopia Therapies, (OTC Pink: TWGL) announced it has formed PsyBioMed – Australia and entered into a letter of intent to jointly conduct clinical trials in Australia using psychedelics to treat mental illness. PsyBioMed – Australia will be a joint venture between Mycotopia Therapies and Melbourne, Victoria based psychedelic research and development company Natural MedTech. 

And finally a 2020 Global Drug Survey found that women are more likely than men to use LSD and magic mushrooms to treat psychiatric conditions and emotional stress.